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Abstract: When a T cell infiltrates a tumor, it is subjected to a variety of immunosuppressive and
regulatory signals in the microenvironment. However, it is becoming increasingly clear that due
to the proliferative and energetically-deregulated nature of tumor cells, T cells also operate at
a metabolic disadvantage. The nutrient dearth of the tumor microenvironment (TME) creates
“metabolic checkpoints” upon infiltrating T cells, impacting their ability to survive, proliferate
and function effectively. In this review, we summarize the basics of tumor cell and T cell metabolism
and discuss recent advances elucidating the individual metabolic checkpoints exerted on T cells that
drive their dysfunction in the TME.
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1. Introduction
Most of the hallmarks of cancer cells can be attributed to the inability to respond to environmental
cues to slow proliferation or induce cell death [1]. These environmental insensitivities are generally
due to DNA mutations, usually occurring during an individual’s lifetime and in response to a variety
of exogenous genetic insults and endogenous modulatory factors [1]. While the initial neoplastic event
is due to these uncorrected DNA mutations, it is widely believed that the progression from neoplasia
to malignancy is due in part to a failure of immunosurveillance [2–4]. The immune system excels at
identifying and eliminating mutated cells, but cancer can evade recognition through a process called
“immunoediting”. The immune system puts selective pressure on the tumor cell population, making it
advantageous for tumor cells to mutate or alter the production of antigens that might be recognized as
foreign by the immune system. Tumor cells also downregulate antigen processing and presentation
machinery, rendering them invisible to the immune system. Thus, if cancerous cells keep mutating,
they can keep evading immune recognition [5].
Concomitant with cancer cells escaping immune recognition and elimination, cancer cells may
begin to utilize additional mechanisms to create an immunosuppressive environment. This can be
induced by the recruitment of immunosuppressive cells (myeloid-derived suppressor cells (MDSCs)
and regulatory T cells) to create a “wound healing” environment and the generation of tolerogenic
signals, such as interleukin-10 (IL-10), transforming growth factor-beta (TGF-β) and extracellular
adenosine [6]. Tumor cells can induce T cell dysfunction through direct receptor-ligand interactions,
expressing co-inhibitory ligands, such as programmed death-ligand 1 (PD-L1) to inhibit CD8+
tumor-infiltrating lymphocytes’ (TIL) function through programmed death-1 (PD-1), a process further
enhanced through contact with the immune system [7]. T cell function can also be inhibited by other
co-inhibitory “checkpoint” molecules, such as cytotoxic T lymphocyte-associated protein-4 (CTLA-4),
T cell immunoglobulin and mucin domain containing-3 (Tim-3), lymphocyte activating gene 3 (Lag3)
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and T cell immunoreceptor with Ig and ITIM domains (TIGIT), which are upregulated on the surface
of T cells after activation and remain highly expressed on T cells in the tumor microenvironment (TME)
due to persistent activation signals. Ligation of these co-inhibitory checkpoint molecules results in
downregulation of T effector function.
One of the most promising new immunotherapies, generally termed “checkpoint blockade”,
utilizes monoclonal antibodies specific to either the co-inhibitory ligand or receptor to block their
interaction [8]. Anti-CTLA-4 and anti-PD1/PD-L1 were among the first in clinical trials, showing
promising objective clinical responses [9,10]. However, these therapies are only effective in a subset
of patients, and the biomarkers of responsiveness to these immunotherapies remain elusive [11].
This likely indicates that immunosuppression from these “immunologic” sources does not account
for the whole suppressive microenvironment. In this review, we postulate that tumor cells are also
immunosuppressive due to a suppressive metabolic microenvironment characterized by a lack of
crucial carbon sources and intermediates needed for T cell function.
2. Metabolism in the Tumor Microenvironment
The driving force behind the malignancy and morbidity of cancer is its ability to proliferate
unrestrained. While individual cancer cells may be insensitive to growth inhibition, it is not without
cost for these cells. Their unrestrained growth requires the cancer cells to utilize aerobic glycolysis
(also called the “Warburg effect”, after Otto von Warburg who initially described it) over oxidative
metabolism [12,13]. This occurs when cells convert glucose-derived pyruvate into lactic acid, rather
than acetyl-CoA to fuel oxidative phosphorylation (OXPHOS). While this glucose fermentation occurs
in all cells when oxygen is limiting, most tumors cells acquire a metabolic adaptation to perform
glycolysis even in the presence of oxygen [14].
Why glycolysis occurs in cancer cells has been a matter of debate since its discovery [12]. It was
originally hypothesized that aerobic glycolysis may occur in cancer cells due to mitochondrial damage,
but it is now clear that cancer cells still utilize their mitochondria for oxidative metabolism [15].
Thus, it may seem perplexing why a tumor cell might choose this bioenergetically unfavorable
pathway, as biochemical studies show that glycolysis generates eighteen times less ATP per mole of
glucose than OXPHOS [16,17]. However, there are other important considerations for the cellular
metabolism of tumor cells. First, while glycolysis generates less ATP per mole of glucose compared
to OXPHOS, the kinetics of this reaction are considerably different: glycolysis generates ATP nearly
a hundred times faster than OXPHOS, such that if a tumor cell could compete for glucose, it could meet
its metabolic demands [16,17]. Second, by utilizing aerobic glycolysis, the cancer cell can regenerate
the reductive molecule NAD+, which is utilized in the initial steps of glycolysis, as well as in other
essential metabolic pathways in the cell. Third and most importantly, aerobic glycolysis serves to free
a portion of mitochondrial function to perform anabolic metabolism: producing the lipids, amino acids
and nucleotides needed to generate daughter cells [14,18]. Due to the high metabolic demands of these
highly proliferative cells, cancer cells utilize aerobic glycolysis and use up essential metabolites in
the surrounding environment, secreting lactic acid as metabolic waste of the glycolytic pathway [14].
As a result, this microenvironment has low glucose, low oxygen and a low pH [17,19–21]. These crucial
metabolites, especially oxygen, are replenished poorly due to dysregulated angiogenesis caused by
the tumor [22]. Low oxygen levels also help induce a glycolytic program by increasing HIF-1α
expression [23]. HIF-1α turns on gene expression programs to directly inhibit OXPHOS, further
enforcing tumor cell aerobic glycolysis [24].
The altered metabolism of tumor cells was posited by Warburg to be not only a characteristic of
malignancy, but even causative of the malignant phenotype [12]. While the last several decades have
explored exactly why and how developing cancer undergoes this type of metabolic transformation,
it is clear that this emerging hallmark of cancer does not only impact the cancer cells themselves [1].
This hunger in cancer cells for available nutrients to fuel their unrestrained proliferation creates
a bioenergetic sink for any cell that enters the tumor microenvironment. It is now understood that a lack
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of metabolites and oxygen, as well as high intratumoral acidity, act as additional immunosuppressive
mechanisms the tumor exploits to prevent infiltrating T cells from functioning efficiently (Figure 1).
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Figure 1. Tumor cell energetics dictate the metabolic landscape of the TME. Tumor cells utilize 
glycolysis and oxidative phosphorylation metabolism, causing depletion of particular environmental 
metabolites and inhibiting TIL in different ways. Glycolytic tumors primarily utilize glycolysis for 
energy, creating a TME that has low glucose and high acidity and lactate. This inhibits T cell function 
by limiting fuel for T cell glycolysis, as well as inhibiting T cell cytokine production and proliferation. 
Oxidative tumors primarily utilize OXPHOS and their mitochondria for energy, creating a TME that 
has low oxygen, low fatty acids and low amino acids. This inhibits T cell function by limiting oxygen 
for T cell OXPHOS, as well as inhibiting T cell mitochondria from producing ATP and ROS. Low ATP 
production has the downstream consequence of inhibiting mTOR activity. Tumor cells that are both 
glycolytic and oxidative inflict complete metabolic insufficiency on T cells, while quiescent tumors 
with minimal metabolic demands can better hide from immunosurveillance via reduced proliferation. 
Abbreviations: tumor microenvironment (TME), tumor-infiltrating lymphocyte (TIL), oxidative 
phosphorylation (OXPHOS), reactive oxygen species (ROS), and mechanistic target of rapamycin 
(mTOR). 
3. Metabolic Regulation of T Cells 
Recent studies have demonstrated the essential role of metabolism for immune cells, beyond 
simply growth or death decisions. The link between fuel source and metabolic program and how 
these impact immune cell phenotype and function are an active area of research [25]. One of the first 
contributions to the immunometabolism field was looking at the relative contributions of glycolysis 
and OXPHOS during lymphocyte activation [26]. It was noted that when lymphocytes were activated 
via receptor crosslinking with phytohemagglutinin, the lymphocytes (like tumor cells) also 
underwent aerobic glycolysis. Later studies revealed that T cells use both glycolysis and OXPHOS to 
generate ATP, and both pathways are required for in vitro proliferation [27]. As T cells also undergo 
aerobic glycolysis upon activation, they have high energy demands from their environment in order 
to proliferate and function. To better understand the basics of T cell metabolism, the following section 
will review when T cells change their metabolic demands, as well as how environmental nutrient 
sensing can change the fate of T cells. With this understanding, we will then see how energy sensing 
and utilization becomes dysfunctional in the TME when T cells need to compete with tumor cells for 
glucose and other nutrients. 
3.1. T Cells Change Their Metabolic Demands upon Activation 
Of all immune cells, T cells in particular have become a research focus, as the progression 
through activation comes with distinct metabolic changes [28]. Naive T cells, which are required to 
be quiescent for a lifetime, have low metabolic demands. The maintenance of this quiescent state 
requires minimal OXPHOS, dividing only to maintain the clonal repertoire throughout life. The  
pro-survival cytokine interleukin-7 (IL-7) is necessary for the maintenance of these quiescent  
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rapamycin (mTOR).
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3.1. T Cells Change Their Metabolic Demands upon Activation
Of all immune cells, T cells in particular have become a research focus, as the progression through
activation comes with distinct metabolic changes [28]. Naive T cells, which are required to be quiescent
for a lifetime, have low metabolic demands. The maintenance of this quiescent state requires minimal
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OXPHOS, dividing only to maintain the clonal repertoire throughout life. The pro-survival cytokine
interleukin-7 (IL-7) is necessary for the maintenance of these quiescent cells [29]. IL-7 is important for
the uptake of glucose through glucose transporter 1 (Glut1) for the maintenance of ATP levels [30].
Thus, these quiescent T cells maintain minimal metabolic demands until activated, preserving fuel in
the environment for those T cells that have entered their effector phase.
When a T cell encounters its antigen, its first task is to begin cellular growth and to prepare for
cell division. Since antigen-specific naive T cells are so few in numbers, it is important to proliferate
quickly to generate sufficient numbers of effector cells; but this proliferation has high metabolic
demands. Thus, like highly proliferative tumor cells, activated T cells utilize glucose as a primary
fuel source [31]. Glut1 is upregulated upon T cell activation, through T cell receptor (TCR) and
CD28-induced serine/threonine kinase Akt activation, allowing activated T cells to increase their
glucose uptake eighteen-fold higher than naive T cells [32]. This allows cells to use aerobic glycolysis
for anabolic cell growth [30]. Failure to upregulate metabolic pathways upon T cell activation leads to
a hyporesponsive phenotype much like clonal anergy, a state in which even a full antigenic stimulation
cannot induce a T cell response [33]. Similar to an anergic T cell, T cells that have been activated in
nutrient-poor conditions will become unresponsive to future stimulation. This finding highlights the
important link between metabolism and T cell function: starving a T cell can have lasting effects on its
ability to perform in the future, even in nutrient-rich conditions.
While adopting aerobic glycolysis can keep up with ATP demands, regenerate NAD+ and promote
anabolic pathways for mitochondrially-derived substrates, recent studies have also revealed that
glycolysis may contribute to effector functions directly. It has long been known that glycolytic enzymes
can “moonlight” as RNA-binding proteins when not performing enzymatic reactions [34]. Indeed,
T cell-derived glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was shown to bind interferon
gamma (Ifng) mRNA in resting, non-glycolytic T cells, suggesting that glycolysis promotes cytokine
secretion, in part, by relieving post-transcriptional repression of cytokine messages [27].
T cells continue to utilize aerobic glycolysis during the effector phase of their activation, but switch
back to primarily utilizing OXPHOS as they become memory cells [35]. The formation of memory
T cells leads to a larger mitochondrial reserve than naive T cells, termed spare respiratory capacity [35].
The gamma-chain cytokine interleukin-15 (IL-15), important for forming long-lasting memory T cells,
also increases mitochondrial biogenesis and the expression of the mitochondrial enzyme carnitine
palmitoyltransferase 1a (CPT1a), a rate-limiting enzyme in fatty acid oxidation [36]. As such, it is
thought that the increase in memory T cell mitochondria primes the cells for a quick recall response
with a bioenergetic advantage over naive T cells. Memory T cells in a recall response can also switch to
glycolysis in an Akt-dependent manner, but have higher glycolytic flux and increased upregulation
of glycolytic enzymes, such as GAPDH, than do naive T cells [37]. However, antigen-experienced
T cells also have additional metabolic demands, as evidenced by the fact that memory T cells also
rely on fatty acid oxidation. For instance, when CD8 T cells lack TNF receptor associated factor
6 (TRAF6), a signaling molecule downstream of the tumor necrosis factor (TNF) cytokine receptor
superfamily, they are unable to form memory after immunization [38]. TRAF6-deficient T cells show
repression of fatty acid metabolism genes, leading to defective lipid oxidation. Thus, memory T cells
may require a variety of metabolites to fuel their increased mitochondria to carry out their recall
responses more effectively.
The metabolism of T cells is tied directly to proliferation, cytokine production and cytolytic
function: essential functions of an effector T cell. While many of these studies have utilized inhibitors
or genetic targeting to determine the contributions of various metabolic pathways to T cell function,
a pair of recent studies has revealed that these pathways are dynamically regulated even during the
generation of a “typical” T cell response [39,40]. The model for the generation of memory hypothesizes
that T cells have both short-lived effector and memory potential. However, upon contact with
antigen-presenting cell (APC)-bound peptide-major histocompatibility complex (MHC), the T cell
will grow and then divide in an asymmetric manner. The proximal cell to the APC receives the lion’s
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share of signaling molecules and activation signals and becomes fated to be a short-lived, effector
cell, while the distal cell is less proliferative in subsequent divisions and inherits more memory
potential [41]. Interestingly, the metabolic demands of a T cell can also be asymmetrically inherited
upon activation [39,40]. Proximal daughter cells have more Myc and mechanistic target of rapamycin
(mTOR) activity, resulting in part due to asymmetric partitioning of lysosomes and amino acid
transporters. As both Myc and mTOR are important factors for cell proliferation, differentiation
and metabolism, differences in these metabolic programs lead to distinct cell fates for the dividing
daughter cells.
3.2. T Cells Utilize Nutrient Sensing to Dictate Their Differentiation
It is clear that metabolite availability and changes in metabolic pathways can have major effects
on T cell function, but this is largely unsurprising since energy is required to perform any complex
cellular task. However, unlike other renewable cell types present in the body, clonal diversity must be
preserved in T cells. This creates a need for reliance upon nutrient sensing. It would not be favorable for
a T cell to engage an effector response if it could not metabolically support the expansion; subsequent
cell death might eliminate that clone. T cells thus have conscripted the nutrient-sensing machinery to
make more complex fate determinations, rather than growth-or-death decisions.
A key molecule in the nutrient sensing machinery is mTOR. mTOR integrates environmental
signals, such as amino acid and oxygen availability, intracellular ATP concentration, extracellular
growth/survival signals, and cellular activation status. These signals are then utilized to induce
changes in cell size, proliferation, metabolism and survival to respond to extracellular signals and
environmental status [42]. The importance of mTOR in T cells was discovered by its inhibition by
rapamycin, a macrolide antibiotic that is a potent immunosuppressant [43]. Rapamycin was first found
to induce anergy in T cells [44]. Once rapamycin was determined to inhibit mTOR, the signaling
molecule’s role in T cell activation and differentiation was investigated.
mTOR was shown to be the signaling molecule responsible for “full” T cell activation upon
TCR engagement in T cell clones. Further activated and anergic T cells could be distinguished by
mTOR-induced metabolic machinery, which provided evidence for metabolism’s critical role in T cell
functionality [45]. Further exploration of the role of mTOR found that it is essential for T cell lineage
commitment [46]. CD4+ T cells lacking mTOR differentiate into regulatory T cells over Type 1 T helper
(Th1), Th2 or Th17 cells. It is interesting to note the lack of mTOR results in regulatory T cells,
since it could be interpreted as the lack of metabolic cues from a T cell’s environment that defaults
to a regulatory phenotype and that T cell anergy and regulation are very similar from a metabolic
standpoint. CD8+ T cells are also dependent on mTOR signaling; low-dose mTOR inhibition increases
memory T cell precursors and accelerates memory T cell differentiation, somewhat paradoxically as
mTOR is used clinically as an immunosuppressant [47]. As CD8+ memory relies more on OXPHOS
than glycolysis and mTOR activation is associated with glycolysis and AKT activation, low-level mTOR
signaling in CD8 T cells may bias their metabolism towards that which supports a memory phenotype.
mTOR does not signal by itself; rather, it exists as a larger signaling complex with other molecules.
Specific T cell-conditional deletion of mTOR complex 1 (mTORC1) and mTORC2 revealed that these
complexes play distinct roles in directing T cell fate. When mTORC1-dependent Ras homolog enriched
in brain (Rheb) was deleted from CD4+ T cells, they failed to differentiate into Th1 or Th17 T cells,
but Th2 differentiation was intact [48]. Additionally, when mTORC2 signaling was conversely deleted,
CD4+ T cells failed to differentiate into Th2 T cells, but Th1 and Th17 differentiation was intact.
The opposing roles of mTORC1 and 2 in T cell fate determination highlight a T cell’s ability to make
widely different fate decisions based on subtle metabolic environmental differences. This allows
for T cell plasticity and the ability to respond complexly to environmental changes. mTORC1 and
2 were also found to have specific roles in generating effector and memory CD8+ T cell subsets.
Constitutively-active mTORC1 generates glycolytic effector T cells unable to enter the memory phase,
while mTORC1-deficient effector T cells failed to activate an effector response, but maintained memory
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T cell characteristics [49]. The control of T cell fate by mTORC1 and mTORC2 supports the idea that
the T cells have cell-intrinsic potential to be either effector or memory upon activation, rather than
effector T cells differentiating to memory as a progression of activation. The ability of mTOR to sense
the environmental state thus impacts T cell activation and differentiation; nutrient availability can
have a long-term impact on T cell fate.
Outside of mTOR, T cells use other metabolic signaling molecules to sense and respond to their
environment, namely Myc and 5′ AMP-activated protein kinase (AMPK). Myc is essential for glycolytic
reprogramming, with deletion of Myc inhibiting activation-induced glycolysis and glutaminolysis [50].
AMPK senses nutrient deprivation and can limit mTOR activity in low glucose environments [51].
AMPK also impacts T cell differentiation; AMPKα1 knockout T cells are unable to form memory and
display defects in CD4+ Th1 and Th17 differentiation [51,52].
Additional transcription factors can also play a role in how T cells respond to environmental
metabolic cues promoting cellular proliferation, differentiation, or homeostasis. Sterol regulatory-element
binding proteins (SREBPs) are a family of transcription factors that control cholesterol synthesis
and uptake. SREBP family members are upregulated upon T cell activation and are essential to
proliferating CD8+ T cells, required for the increased lipid membrane synthesis needed to generate
daughter cells [53]. Peroxisome proliferator-activated receptors (PPARs), the family of nuclear receptor
transcription factors also involved in lipid metabolism, have also been shown to play a role in T cell
immunoregulation [54]. PPARγ has specifically been shown to be a negative regulator of T cell
activation, regulating interleukin-2 (IL-2) production in activated T cells, and the loss of PPARγ in
T cells contributes to autoimmunity [55,56]. Transcription factor EB (TFEB), a regulator of lysosomal
biogenesis, has been shown to be negatively regulated by mTORC1 [57]. When intracellular metabolites
are high, TFEB is retained in the cytosol, but when nutrients are needed, TFEB disassociates from
mTORC1 and translocates to the nucleus to increase lysosome biogenesis. Lysosomes are important
for mTORC1 activation and further downstream signaling, but the effects of the loss of TFEB in T cells
are still unknown. However, transcription factor A mitochondrial (TFAM) has also been shown to
play a role in T cell lysosomal function [58]. Deletion of TFAM in T cells impairs lysosomal function
and promotes proinflammatory T cell differentiation, linking T cell homeostasis with differentiation.
For mitochondrial function, Yin Yang 1 (YY1) acts as a mediator between mTOR and mitochondrial
biogenesis; mTOR activates YY1 to promote mitochondrial biogenesis via transcriptional coactivator
PPAR gamma coactivator 1 alpha (PGC1α) [59]. These families of transcription factors allow T cells to
integrate environmental metabolite signals, initiating fine-tuned gene programs associated with cell
proliferation, differentiation, and homeostasis.
As described above, T cells rely on metabolism to both become activated and make complex fate
determinations. However, these decisions are often carried out in environments where T cells have
adequate metabolites to carry out these functions. When the microenvironment cannot metabolically
support T cell expansion, the signals to grow and differentiate can be misinterpreted, resulting in
T cell dysfunction.
4. Metabolism of T Cells in the Tumor Microenvironment
When T cells infiltrate the TME, they are subjected to immunosuppressive signals and low
metabolites. These signals impact T cell function in the form of immunologic and metabolic checkpoints
(Figure 2). In this section, we will discuss immunologic and metabolic checkpoints and how they
overlap to suppress effector function in the TME.
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function. When a T cell becomes activated, it upregulates co-inhibitory molecules, such as CTLA-4 
and PD-1, to inhibit further activation. These cell-intrinsic co-inhibitory molecules inhibit mTOR 
function through PP2A or SHP-2 signaling, respectively. Tim-3, another co-inhibitory molecule, can 
activate mTOR through unknown mechanisms. For cell-extrinsic immunologic checkpoints, 
immunosuppressive cells in the TME, such as regulatory T cells and MDSCs, can secrete or convert 
soluble factors, such as TGF-β, IL-10, IL-35, IDO, or adenosine, which suppress T cell activity. TGF-β 
can suppress T cell activity by suppressing mTOR through TGF-βR signaling. IDO also can suppress 
mTOR. For metabolic checkpoints, low glucose has been shown to inhibit IFNγ cytokine translation 
and T cell proliferation. The low pH of the TME prevents the regeneration of NAD+, important as a 
reducing equivalent to drive the mitochondrial TCA cycle forward to generate ATP. TME hypoxia 
can also inhibit the mitochondria by limiting electron acceptors of ATP synthase. This can decrease T 
cell ROS, as well as decrease cellular ATP levels. Low cellular ATP activates AMPK, which can further 
inhibit mTOR activity. Abbreviations include tumor microenvironment (TME), cytotoxic T 
lymphocyte-associated protein-4 (CTLA-4), programmed death-1 (PD-1), mechanistic target of 
rapamycin (mTOR), protein phosphatase 2A (PP2A), SH2-domain containing tyrosine phosphatase 2 
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sequence in the PD-1 cytoplasmic tail, and SHP-2 has been shown to inhibit phosphoinositide  
3-kinase (PI3K) activity, thereby inhibiting downstream Akt and mTOR activity. Forkhead box 
protein o1 (Foxo1), a transcription factor downstream of Akt and mTOR signaling, also intersects 
with co-inhibitory signaling [66]. Impaired Akt and mTOR signaling due to chronic viral infection 
enhances Foxo1 activity, thereby increasing the expression of PD-1 on T cells. Additionally, Tim-3, 
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co-inhibitory signaling [66]. Impaired Akt and mTOR signaling due to chronic viral infection enhances
Foxo1 activity, thereby increasing the expression of PD-1 on T cells. Additionally, Tim-3, which is
found upregulated on exhausted T cells, has been implicated in upregulating ribosomal protein S6,
downstream of the PI3K/Akt/mTOR pathway [67]. Rather than inhibiting mTOR, Tim-3 could be
promoting it, increasing glycolysis and other metabolic functions.
T cells upregulate co-inhibitory molecules to prevent further activation of already activated
cells [8]. This prevents the pathological effects of unrestrained activation and potential autoimmune
or autoinflammatory tissue damage. It makes sense that these co-inhibitory molecules (CTLA-4 and
PD-1) evolved to also inhibit the metabolic phenotype of activation. However, the ligand used to signal
through Tim-3 in the tumor microenvironment and the consequent downstream signaling pathways
are still unclear. However, the idea that Tim-3 might increase mTOR function may help to discover the
true function of Tim-3 on activated T cells.
4.2. Low Glucose and T Cell Function
The importance of glucose for T cell function was first determined in in vitro assays. When T cells
have limited glucose, they decrease their glycolytic flux through a decrease in Akt activity and can
activate proapoptotic B cell lymphoma-2 (Bcl-2) family members to induce apoptosis [68–70]. Recent
work has begun to explore in-depth how the metabolite-deficient TME impacts the effector function of
T cells. Several recent studies in tumor-T cell immunometabolism have focused on understanding how
low glucose availability impacts T cell functionality in the TME [71–73]. Rendering tumor cells more
glycolytic by increasing tumor cells’ glucose uptake makes CD8+ T cells less capable of controlling
tumor growth [71]. It was also shown that tumor cell-specific checkpoint blockade reduces tumor cell
glucose uptake, restoring glucose to the TME, which may be one reason for the success of co-inhibitory
checkpoint blockade as an immunotherapeutic [71]. In addition, another recent study has shown
that the glycolytic metabolite phosphoenolpyruvate is important for sustaining calcium-mediated
nuclear factor of activated T cells (NFAT) signaling to enable conventional CD4+ T cell function in the
tumor [72]. The low glucose TME has also been shown to decrease methyltransferase enhancer of zeste
homolog 2 (EZH2) expression in T cells in the setting of ovarian cancer [73]. Low EZH2 expression
lead to T cell’s decreased ability to perform glycolysis and effector functions and decreased T cell
survival. Therefore, glucose is an essential metabolite for T cell function, but its limited availability in
the TME contributes to metabolically-induced T cell dysfunction.
4.3. Hypoxia and Tumor-Infiltrating T Cell Function
Oxygen availability is low in the TME due to both poor vascularization of the tumor and the
high oxygen consumption of proliferative tumor cells [21,22]. Decreased oxygen tension is a classic
hallmark of the tumor microenvironment, but its effects of hypoxia on T cell function are still
nebulous [1,74]. Much of our understanding of hypoxia’s effect on T cells is derived from genetic
manipulation of the hypoxia sensing machinery: prolyl hydroxylase domain-containing proteins
(PHD), Von Hippel-Lindau (VHL) and hypoxia inducible factor 1 alpha (HIF1α) [74]. HIF1α is
stabilized in hypoxia, but it is also stabilized upon T cell activation, due in part to Myc upregulation
and consequent glycolytic reprogramming [50]. Thus, it is difficult to interpret how the deletion or
overexpression of HIF1α might actually represent a T cell’s response to hypoxia in vivo. Nevertheless,
in several different types of experimental systems, low oxygen seems to decrease T cell proliferation,
with variable effects on cell survival and function [75]. Oxygen availability and its impact on infiltrating
CD8+ T cell function have also begun to be explored by giving supplemental oxygen to tumor-bearing
mice to decrease TME hypoxia [76]. Decreasing hypoxia through respiratory hyperoxia led to increased
T cell infiltration, increased proinflammatory cytokines and improved tumor regression and survival
in mice. Overall, oxygen is an important metabolite needed both for T cell and tumor cell function and
is robustly competed for in the TME.
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4.4. TME Metabolites and Tumor-Infiltrating T Cell Function
The TME has low or altered metabolites compared to different environments in the body. The TME
has low availability of many amino acids, especially glutamine, due to its use as a primary fuel for
tumor cells [77]. Because glutamine is an important amino acid for T cells and a lack of glutamine
prevents T cell activation and differentiation, the low glutamine TME is detrimental for T cell
function [78,79]. The amino acid tryptophan is also low in the TME, due to the tryptophan-metabolizing
enzyme indoleamine 2,3-dioxygenase (IDO) expressed by tumor cells and regulatory immune cells [80].
Both the loss of tryptophan from the environment and the increase of the tryptophan catabolite
kynurenine are immunosuppressive. The amino acid arginine is also low in the TME, due to its
consumption by tumor cells and by myeloid cell arginase-mediated depletion, and arginine is required
in activated and proliferating T cells [81,82]. Lactic acid, the byproduct of deregulated tumor cell
glycolysis, is extraordinarily immunosuppressive, inhibiting T cell function and cytokine production
through both pH-dependent changes, as well as loss of cytosolic NAD+ regeneration [83]. In addition,
extracellular adenosine has been shown to be immunosuppressive. Extracellular ATP, released from
dying cells, can be metabolized by CD39 and CD73 expressed on the surface of regulatory T cells,
MDSCs and tumor cells [84]. This adenosine binds to the adenosine A2A receptor on the surface of
T cells to suppress T cell activity and induce regulatory T cells. Thus, the TME has many metabolic
deficiencies, every one of them detrimental on its own for T cell function. T cell activation may be
crippled in the TME due to this “perfect storm” of metabolically-suppressive signals, acting along
many axes to restrain T cell function.
4.5. Mitochondria and Tumor-Infiltrating T Cell Function
Mitochondria are more than the “powerhouse” of the cell: they are biosynthetic factories, used to
generate the material for daughter cells, providing numbers for a T cell clonal army [18]. Mitochondria
also are essential for T cell effector function, especially to generate reactive oxygen species (ROS)
for T cell cytolytic activity [85]. Recently, even the morphology of mitochondria has been linked to
T cell fate. Activated effector T cells undergo dramatic mitochondrial remodeling, forming punctate
mitochondria caused by fission, while memory T cells are characterized by a fused network of
mitochondria under the control of mitochondrial fusion protein optic atrophy 1 (Opa1) [86]. These
mitochondrial fusion networks have superior oxidative function, an important hallmark of T cell
memory, and function better in solid tumors. It may be that these mitochondrial morphologies impact
T cell function directly, and future studies in mitochondrial and metabolic dynamics will identify how
these crucial processes are dynamically regulated and reprogrammed during the life of the T cell.
However, these processes can be critically regulated in response to cancer.
We have recently shown that T cells lose mitochondrial activity and mass upon entering the
TME, a process that correlates with upregulation of co-inhibitory checkpoint molecules [87] (Figure 3).
This loss in mitochondrial mass is caused by decreased mitochondrial biogenesis, due in part to
repression of the transcriptional co-activator PGC1α. Chronic Akt signaling was found to drive down
PGC1α in tumor T cells, and PGC1α levels could be partially restored with Akt inhibition, consistent
with the finding that Akt inhibition promotes the expansion of quantitatively and qualitatively
better TIL for adoptive cell therapy [88]. Enforcing PGC1α expression via genetic reprogramming
also increased mitochondrial fitness in TIL, improving T cell functionality and decreasing tumor
burden when adoptively transferred into a melanoma mouse model [87]. Similar mitochondrial
deficiencies have been observed in T cells in chronic viral infection, suggesting that repressed PGC1α
acts as a driving factor for decreased mitochondrial activity [89]. Thus, improving mitochondrial
quantity by programming mitochondrial biogenesis or improving the quality by promoting fusion and
morphologic changes may serve to endow T cells with greater persistence and function in the nutrient
dearth of the TME.
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CD8+ TIL in the TME have chronically-activated Akt. Akt, either acting directly or indirectly via 
Foxo1, inhibits the mitochondrial biogenesis transcriptional coactivator, PGC1α. Repressed 
mitochondrial biogenesis leads to mitochondrial insufficiency, causing the CD8+ TIL to have 
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o1 (Foxo1), PPAR gamma coactivator 1 alpha (PGC1α), and reactive oxygen species (ROS). 
5. Conclusions 
The success of several immunotherapeutic approaches in cancer has generated incredible 
interest in tumor immunology, promoting the search for the next big checkpoint that might surpass 
PD-1. We would argue that along with the immune checkpoints that inhibit T cell responses in the 
TME, there are a variety of metabolic checkpoints that negatively impact TIL function. From low 
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more “metabolically aggressive” tumors than others. Thus, understanding the metabolic qualities of 
a patient′s tumor could provide clinicians with biomarkers to better understand the specific 
metabolically-inhibitory nature of a cancer. Furthermore, understanding the precise energetic defects 
in TIL and the effect of the microenvironment on these defects has the promise to not only synergize 
to improve existing immunotherapies, but potentially provide novel avenues to re-invigorate 
endogenous T cells by directly relieving these potent metabolic checkpoints. 
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